Introduction And Importance: Ulcerative colitis is a chronic condition characterized by continuous inflammation of the rectum and colon. Its clinical complications extend beyond the gastrointestinal tract to involve multiple systems, including musculoskeletal, hepatobiliary, cardiovascular, and ocular manifestations. Takayasu arteritis and ankylosing spondylitis are two autoimmune inflammatory disorders that have previously been reported as coexisting conditions associated with ulcerative colitis. is an autoimmune-mediated inflammation of the thyroid gland causing the release of thyroid hormones and is considered a variant form of chronic autoimmune thyroiditis (Hashimoto's thyroiditis).

Case Presentation: The authors report a case of a 32-year-old Caucasian man with a 3-year history of ulcerative colitis who presented to our clinic in 2015, complaining of chronic lower back pain that alleviates with exercise but does not relieve with rest. Based on our physical exam findings and lab results, ankylosing spondylitis was diagnosed using Assessment of Spondylarthritis International Society and New York criteria. Computerized tomography angiography was performed and demonstrated stenosis in multiple arteries. These findings satisfied the American College of Rheumatology criteria for Takayasu's disease. After the Infliximab was started, the patient had significant symptomatic improvement.

Clinical Discussion: The use of biological therapy plays a key role in the treatment of many autoimmune illnesses. The patient was considered resistant and nonresponsive to treatment; thus, biological therapy was indicated, and infliximab was administered, resulting in a significant clinical improvement and remission of all illnesses.

Conclusion: The authors aim to report a rare coexistence of ulcerative colitis, ankylosing spondylitis, Takayasu's arteritis and silent thyroiditis. And the authors believe this can aid in diagnosing and management of rare diseases.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543149PMC
http://dx.doi.org/10.1097/MS9.0000000000002495DOI Listing

Publication Analysis

Top Keywords

ulcerative colitis
20
ankylosing spondylitis
16
colitis ankylosing
8
spondylitis takayasu's
8
takayasu's arteritis
8
arteritis silent
8
silent thyroiditis
8
biological therapy
8
colitis
5
comorbidity ulcerative
4

Similar Publications

Letter: Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: Authors' Reply.

Inflamm Bowel Dis

December 2024

Division of Gastroenterology, Hepatology & Nutrition, Allegheny Health Network, Pittsburgh, PA, USA.

View Article and Find Full Text PDF

Introduction: Hypoalgesic inflammatory bowel disease (IBD) may provide critical insights into human abdominal pain. This condition was previously associated with homozygosity for a polymorphism (rs6795970, A1073V; 1073 val/val ) related to Na v 1.8, a voltage-gated sodium channel preferentially expressed on nociceptors.

View Article and Find Full Text PDF

ASYMPTOMATIC INFLAMMATORY BOWEL DISEASE DIAGNOSED DURING COLORECTAL CANCER POPULATION SCREENING IN CATALONIA: CHARACTERISTICS AND NATURAL HISTORY.

Clin Transl Gastroenterol

December 2024

Gastroenterlogy Department. Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA). Sabadell, Catalunya, Departament de Medicina, Universitat Autònoma de Barcelona.

Introduction: Inflammatory bowel disease (IBD) is usually diagnosed when symptomatic. Prognosis and evolution of preclinical IBD is largely unknown. However, colorectal cancer screening programs (CRCSP) detect a subset of IBD patients with no symptoms.

View Article and Find Full Text PDF

Protective Role of Selenium-Binding Protein 1 (SELENBP1) in Patients with Ulcerative Colitis.

Metabolites

December 2024

Inflammatory Bowel Disease Clinic, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City 14080, CP, Mexico.

Background: The expression of selenium-binding protein 1 (SELENBP1), a molecule responsible for the absorption of selenium in the colon, is crucial for its immunoregulatory effect, but this phenomenon has not been studied in patients with UC. The present study aimed to determine the clinical outcome of SELENBP1 expression in colonic tissue from patients with UC.

Methods: The relative mRNA expression of SELENBP1 was analyzed in 34 patients with UC and 20 controls.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!